Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
3416-24-8
Molecular formula
C6H13NO5
Molecular weight
179.17 g/mol
Drug class
Amino sugarglycosaminoglycan and cartilage-matrix precursor
Mechanism of action
A substrate for synthesis of glycosaminoglycans and proteoglycans in connective tissue. Oral supplementation has been proposed to influence cartilage metabolism, but a disease-modifying mechanism for osteoarthritis has not been established.
Indications / reported uses
Used as a dietary supplement for osteoarthritis symptoms in some countries; not a universally approved disease-modifying treatment, and efficacy evidence is inconsistent
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Glucosamine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Glucosamine Permitted Daily Exposure (PDE) report (the Glucosamine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Glucosamine Occupational Exposure Limit (OEL) report (the Glucosamine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.